concurrent venous thrombotic event in our group (in a patient without aPL-Abs). The presence of aCL was associated with extracranial large vessel vasculitis (RR 1.8 (95% CI 1.1-2.9)). Double-or triple-positivity for any combination of "classic" aPL (LA and/or aCL and/or abeta2GP1) emerged as a marker of severe visual manifestations (RR of 2.1 (95% CI 1.1-4.3) for permanent or transient visual loss in case of double or triple aPL positivity vs. LA, aCL and aβ2GP1 negative cases). At least 1 year follow-up data (median (IQR) of 103 (54; 105) weeks) were available for 73 patients. 32 patients (43.8%) relapsed, most frequently those with positive aβ2GP1 (62.5%). Background: Systematic treatment used in ocular involvement of Behçet's disease are corticosteroids, synthetic and biological immunosuppressants. The possible irreversible ophthalmological complications make it a priority to know the efficacy of these drugs. Objectives: To analyze the efficacy and safety of biological therapy vs. Cyclosporin A (CsA), azathioprine (AZA), or placebo in reducing the number of uveitis relapses and improving visual prognosis in patients with Behçet. Methods: Systematic search of the literature in MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials from its inception until August 22, 2016. In additional manual search in international conferences and in the references of included studies. Selection criteria: 1) adults with Behçet's disease and uveitis, 2) Biological therapies, 3) placebo or active comparator with CsA or AZA, 4) outcome measures to evaluate efficacy: number of recurrence of uveitis, visual prognosis, cystic macular edema, retinal vasculitis, vitritis, hypopyon and or adverse events. Meta-analyses, systematic reviews, clinical trials, and observational studies of >10 control patients were included. The selection, review and evaluation of the quality of the articles was carried out by 2 independent reviewers. The Oxford scale was used to determine the quality of studies. Results: Of 256 articles, 9 met the inclusion criteria: 3 retrospective observational and 6 randomized clinical trials in 378 patients with Behçet and refractory uveitis to synthetic corticosteroids and/or immunosuppressants. The age range was 9-63 years, with male dominance and a follow-up period of 6-36 months. The different treatments: 3 observational studies compared infliximab (IFX) with CsA and IFX with CsA associated with AZA or methotrexate (MTX) and IFNα2a with AZA associated with CsA; 2 clinical trial (CT) compared adalimumab (ADA) with placebo; 1 CT RTX associated with MTX with ciclofosfamide (CFM) associated with AZA; 1 CT secukinumab (SECUK) with placebo; Another daclizumab (DACL) with placebo and the last pegIFN-α-2b with systemic and/or immunosuppressive corticosteroids. Adverse events were recorded as secondary outcomes in the 9 studies. Conclusions: With variable evidence, IFX appears to be safe and more effective than CsA in reducing short-term uveitis relapse and the number of severe long term complications and retinal vasculitis flares. RTX is similar to CYA associated with AZA in improving short term inflammatory activity. ADA is more effective than placebo as a corticosteroid sparing, achieving early and sustained control in patients with intermediate, posterior, or active uveitis. PegIFNα-2b significantly reduced the dose of corticosteroids, and improved the quality of life. Treatment with IFNα-2a reduces the uveitis/year relapse rate and improves visual acuity. SECUK and DACL, are not effective in reducing uveitis flares but could have an effect on immunosuppressants sparing. The results of this review support the benefit of performing more well-designed comparative studies with IFX, ADA, RTX and IFN-α. Objectives: Behcet's syndrome (BS) is an autoimmune disease characterized by chronic inflammation and endothelial dysfunction. There are only a few studies examining the relationship between neutrophil-lymphocyte ratio (NLR), mean platelet volume (MPV), platelet-lymphocyte ratio (PLR) and BS. The aim of this study was to determine NLR, PLR and MPV levels and their association with disease activation in BS patients with mucocutaneous, ocular and vascular involvement. Methods: The study included 259 patients with BS and 41 healthy individuals. Age, sex, total white blood counts, neutrophil, platelet, mean platelet volume and lymphocyte counts of the patients were recorded. Patients with inflammatory bowel, hematological, infectious, cardiovascular diseases, hyperlipidemia, chronic liver, chronic kidney disease, hypertension, diabetes mellitus, chronic obstructive pulmonary disease, malignancy and corticosteroid use were excluded from the study. Of 259 patients, 163 had active disease (75 active mucocutaneous (MC), 40 active ocular, 48 active vascular involvement) and 96 had inactive disease. MPV, NLR and PLR values of the patients were compared between the groups. P value <0.05 was considered significant. Results: Age and sex were similar between the groups. We compared the MPV, NLR and PLR values of patients with active and inactive disease. NLR and PLR were significantly higher while MPV was lower in the active group than the inactive and control groups (Table 1) . Statistically significant higher PLR and NLR were found in the active MC and vascular groups, significantly lower MPV was seen only in vascular active group. This significance was not seen in active ocular group (Table 2) . We also evaluated the same patient's active and inactive periods of the disease, lower MPV, higher NLR and PLR values were seen MC and vascular groups (for all groups p<0,05). When the active 3 groups were compared within themselves, the MPV value was significantly lower and NLR and PLR values were significantly higher in vascular group than active ocular and active mucocutaneous groups (p=0.033, <0.001, 0.001, respectively). 
Conclusions:
The low MPV and the high NLR and PLR are found in the active disease, which is especially significant in vascular and mucocutaneous groups.
In the light of our findings, NLR and PLR were associated with the activity of BS especially with vascular involvement. The low MPV and the high NLR and PLR.
The low MPV and the high NLR and PLR may be useful disease activity markers in behcet's disease. Background: Unlike other systemic autoimmune diseases (rheumatoid arthritis or systemic lupus erythematosus), the mechanisms involved and the association between ANCA vasculitis with cardiovascular risk factors (CVRF) or cardiovascular events (CVE) are unknown. There may be a phenomenon of "early" atherosclerosis that contributes to an increased cardiovascular risk. This process would not be explained only by the co-existence of the classics CVRF. Objectives: We reviewed the prevalence of classical CVRF and CVE in a cohort of patients diagnosed with ANCA vasculitis. We analyzed whether the appearance of these factors was prior to or subsequent to the diagnosis of the disease or during its evolution. Methods: A descriptive cross-sectional analysis of the classic CVRF and CVE was analyzed in a cohort of patients with ANCA positive vasculitis in follow-up in the Autoimmune Diseases Division of a Spanish hospital. The main demographic characteristics, type of vasculitis and the presence of arterial hypertension, type 2 diabetes mellitus (T2DM), dyslipemia, smoking and obesity were reviewed. Likewise we analyzed CVE (heart failure -HF-, acute coronary syndrome -ACS-, stroke or transient ischemic attack -TIA-and peripheral arteriopathy -PA-) and if each factor was presented at the diagnosis of the disease or they appeared during the evolution after starting immunosuppressive treatment.
Results: A total of 35 patients were studied: 21 women (60%) and the average age was 53 years old. A number of 15 were microscopic polyangiitis, 9 granulomatosis with polyangiitis and 11 allergic granulomatous angiitis. Twenty one patients presented hypertension, 9 of them (42.9%) developed it after the diagnosis of vasculitis. From 7 patients with diabetes mellitus, 5 of them were before diagnosed with vasculitis. Nineteen presented dyslipemia and 9 of them (47.4%) presented lipid alteration during the evolution of vasculitis. Overweight/obesity was evident in 4 of the 11 cases after the diagnosis of vasculitis. Only 5 patients did not have a cardiovascular event. ACS was observed in 3 patients, HF in 2 and PA in 1 patient. There were no cases of TIA or ischemic stroke. Four of them had dyslipidemia (3 after diagnosis of vasculitis) (p=0.18) and 3 had hypertension (2 after diagnosis of vasculitis, p=0.66). Three patients were overweight or obese (p=0.3) and two had T2DM (p=0.2), both of them appeared after the diagnosis. Previous history of smoking was observed in 4 of the 5 patients (p=0.06). In 3 patients (71.4%) the cardiovascular event was recorded prior to vasculitis diagnosis and only in 2 cases it occurred during the evolution.
This study shows that a high percentage of patients with ANCA vasculitis also presents some type of classic CVRF despite of CVE were not elevated. The diagnosis and treatment of ANCA-positive vasculitis did not statiscally correlate with a greater number of CVE, therefore it would be necessary to carry out studies with a larger number of patients in order to establish conclusions. It is not well defined that weight may have these factors in the prognosis of patients with ANCA vasculitis. These data suggest the need to maintain a close monitoring and therapeutic approach of classic CVRF in this relatively young group of patients. Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is a disorder characterised by systemic small vessel vasculitis, that occurs typical in patients with a positive history of late-onset asthma and allergic rhinitis. Cardiac involvement is the major cause of mortality. There is required a standardised method to assess cardiac involvement in EGPA. Objectives: To assess the clinical and imagistic caracteristics of EGPA patients with cardiac involvement in a tertiary referral hospital. Methods: Fourteen patients (pts) with EGPA were retrospectively analysed between 2010-2016, in Rheumathology Departament in Cluj-Napoca. All patients were screened for cardiac involvement by electrocardiogram (ECG) and cardiac ultrasonography (CUS). Cardiac involvement was defined as follows: ventricular hypertrophy, kinetic abnormalities, valvulopathy, pericardial effusion or diastolic dysfunction. Cardiac magnetic resonance (CMR) and coronarographie was assessed in 4 pts with ECG or CUS abnormalities. Results: Characteristics of EGPA patients is detailed in table 1. Six out of 14 pts had cardiac involvement (table 2). Only one patient was symptomatic. CMR abnormalities were: endocardial fibrosis in 2 pts, subepicardial inflammation 
